Safety and efficacy of Peginterferon alfa 2a (pegasys) given once weekly and once monthly in patients with essential thrombocythaemia

Trial Profile

Safety and efficacy of Peginterferon alfa 2a (pegasys) given once weekly and once monthly in patients with essential thrombocythaemia

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2014

At a glance

  • Drugs Peginterferon alfa-2a (Primary)
  • Indications Essential thrombocythaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Sep 2014 New trial record
    • 10 Dec 2013 Primary endpoint: Haematological response to Pegasys at 12 months was met
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top